There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Conmed (CNMD – Research Report), Resmed (RMD – Research Report) and Bristol-Myers Squibb (BMY – Research Report) with bullish sentiments.
Conmed (CNMD)
In a report issued on October 26, Robbie Marcus from J.P. Morgan maintained a Buy rating on Conmed, with a price target of $135.00. The company’s shares closed last Monday at $97.57.
According to TipRanks.com, Marcus is a 5-star analyst with an average return of
Currently, the analyst consensus on Conmed is a Moderate Buy with an average price target of $122.67, implying a 27.4% upside from current levels. In a report issued on October 25, Stifel Nicolaus also maintained a Buy rating on the stock with a $120.00 price target.
See today’s best-performing stocks on TipRanks >>
Resmed (RMD)
In a report issued on October 27, David Low from J.P. Morgan maintained a Buy rating on Resmed, with a price target of $160.00. The company’s shares closed last Monday at $137.45, close to its 52-week low of $132.24.
According to TipRanks.com, Low is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed with a $185.20 average price target, a 34.5% upside from current levels. In a report issued on October 27, Morgan Stanley also upgraded the stock to Buy with a $169.00 price target.
Bristol-Myers Squibb (BMY)
In a report issued on October 27, Chris Schott from J.P. Morgan maintained a Buy rating on Bristol-Myers Squibb, with a price target of $70.00. The company’s shares closed last Monday at $51.25, close to its 52-week low of $49.49.
According to TipRanks.com, Schott is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol-Myers Squibb with a $62.54 average price target, which is a 20.9% upside from current levels. In a report issued on October 27, Truist Financial also maintained a Buy rating on the stock with a $68.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CNMD:
- Conmed price target lowered to $119 from $140 at Needham
- Conmed price target lowered to $130 from $145 at Piper Sandler
- Conmed price target lowered to $107 from $123 at Wells Fargo
- Conmed narrows FY23 adjusted EPS view to $3.45-$3.55 from $3.40-$3.55
- Conmed reports Q3 adjusted EPS 90c, consensus 83c
